Compare ESP & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | CRDL |
|---|---|---|
| Founded | 1928 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 154.1M |
| IPO Year | 1995 | 2017 |
| Metric | ESP | CRDL |
|---|---|---|
| Price | $68.44 | $1.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $64.00 | $8.67 |
| AVG Volume (30 Days) | 13.0K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ 31.88 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $43,950,872.00 | N/A |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $38.43 | ★ N/A |
| Revenue Growth | ★ 13.46 | N/A |
| 52 Week Low | $29.12 | $0.88 |
| 52 Week High | $68.01 | $1.59 |
| Indicator | ESP | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 76.52 | 69.76 |
| Support Level | $42.46 | $0.95 |
| Resistance Level | N/A | $1.59 |
| Average True Range (ATR) | 2.37 | 0.10 |
| MACD | 1.22 | 0.01 |
| Stochastic Oscillator | 85.70 | 95.74 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.